Navigation Links
OncoGenex Pharmaceuticals to Release Second Quarter 2009 Financial Results
Date:8/3/2009

BOTHELL, WA and VANCOUVER, Aug. 3 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals (NASDAQ: OGXI) announced today that the Company will announce second quarter financial results on Thursday, August 6, 2009. OncoGenex will host a conference call and live webcast at 4:30 p.m. EDT that afternoon to discuss quarterly results.

The webcast can be accessed on the Investor Relations page of the OncoGenex Web site at www.oncogenex.com. Alternatively, you may access the live conference call by dialing 877-548-7912 (U.S. Canada) or 719-325-4897 (International). A webcast replay will be available approximately two hours after the call and will be archived on www.oncogenex.com for 90 days.

About OncoGenex Pharmaceuticals

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate that has completed five Phase 2 clinical trials in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 is in Phase 1 clinical development; SN2310 has completed the Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development. More information about OncoGenex is available at www.oncogenex.com.


'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. OncoGenex Pharmaceuticals Completes $9.5 Million Registered Direct Offering
2. OncoGenex Pharmaceuticals to Raise $9.5 Million Through Sale of Common Stock
3. OncoGenex Pharmaceuticals Added to Russell Indexes
4. OncoGenex Pharmaceuticals Files Shelf Registration Statement
5. OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer
6. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
7. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
8. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
9. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
10. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
11. OncoGenex Reports First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... inventions licensed to biotechnology firms has revealed early ... these roadblocks, the researchers suggest that better communication ... could lead to faster commercialization down the road. ... made in university laboratories and licensed to biotechnology ... which have a high failure rate. But a ...
(Date:8/20/2014)... succeeded in measuring vibrational motion of a single molecule ... vibration of a single molecule differs from the behaviour ... performed at the University of California, Irvine, where post-doctoral ... as a visiting fellow under professor Vartkess A. Apkarian, ... was lead by Professor Eric O. Potma. The results ...
(Date:8/20/2014)... High performance computing (HPC) will be ... climate and Earth system model to address the ... Eight national laboratories, including Lawrence Livermore , ... Atmospheric Research, four academic institutions and one private-sector ... laboratories include Argonne, Brookhaven, Lawrence Berkeley, Los Alamos, ...
(Date:8/20/2014)... 2014  PAREXEL International Corporation (NASDAQ: PRXL ... the Baird Healthcare Conference in New York.  Ingo ... will be making a presentation on PAREXEL and discussing ... 3, 2014. A live webcast of the ... PAREXEL,s website at www.PAREXEL.com in the Upcoming ...
Breaking Biology Technology:Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3Seeing a molecule breathe 2New Project Is the ACME of Addressing Climate Change 2New Project Is the ACME of Addressing Climate Change 3PAREXEL International To Present At Baird Healthcare Conference 2
... and adults, HIGHLANDS RANCH, Colo., Dec. 19 ... treatment services to,include a detox program. The new program ... and the hospital has added several new physicians that,specialize ... and,mental illness)., Teen suicide rates nationally are on ...
... Calif., Dec. 19 Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA ... MD, FACC to its Board of Directors. Dr. Barron ... at Genentech,where he leads the Development organization, which is ... joined Genentech in 1996 as a clinical scientist and ...
... CLEVELAND, Dec. 19 Cleveland Medical Devices ... $1.5 million in NIH SBIR,Phase II Continuation ... and Stroke (NINDS). The grant will fund ... quantitative motor assessment system,for evaluating Parkinson,s disease ...
Cached Biology Technology:Highlands Behavioral Health Hospital Unveils New Substance Abuse Detox Program 2Alexza Elects Dr. Hal V. Barron to Its Board of Directors 2Alexza Elects Dr. Hal V. Barron to Its Board of Directors 3CleveMed Receives $1.5 Million in NIH Funding to Further Develop a Portable System for Monitoring Parkinson's Disease Motor Symptoms 2
(Date:8/21/2014)... the Fram Strait is a key region in the global ... Greenland and Svalbard warm Atlantic water flows to the north ... Arctic water masses and sea ice push their way out ... of the Atlantic water cools here on its way to ... the water caused in this manner drives the global band ...
(Date:8/21/2014)... feeding tube connectors, designed by an international standards process, ... , According to an invited review published in the ... ( NCP ), the official journal of the American ... connectors will greatly reduce the occurrence of misconnection that ... Small-bore connectors, which are used to join medical devices, ...
(Date:8/21/2014)... Acute pancreatitis involves the pancreas digesting itself resulting in ... in the UK around 20,000 patients are diagnosed with ... immediate cure and treatment is restricted to intravenous fluid ... the Faculty of Life Sciences, who led the research, ... reflux from gall stones and excessive alcohol intake combined ...
Breaking Biology News(10 mins):Arctic sea ice influenced force of the Gulf Stream 2Arctic sea ice influenced force of the Gulf Stream 3New feeding tube connectors will improve patient safety 2Insulin offers new hope for the treatment of acute pancreatitis 2
... target for a drug seems very promising on paper; ... of telomerase inhibitors,to treat cancer; they are supposed to ... cells. Yet, something in the cell,seems to block their ... do then? Scrap the project? Look for something,else? Hell ...
... in humans in forests between Gabon and the Republic ... animal carcasses, according to a study by the Wildlife ... the February edition of the journal Emerging Infectious Diseases, ... Ebola between 2001 and 2003 produced positive results, and ...
... by human activity and the extinction of species around ... warns a Canadian zoologist. This ecological damage also endangers ... , Dr. Daniel (Dan) Brooks, a parasitologist at the ... is linked to the emergence of new human and ...
Cached Biology News:Combination therapy boosts effectiveness of telomere-directed cancer cell death 2Study Links Ebola Outbreaks To Animal Carcasses 2Ecological destruction fuels emerging diseases 2
... exciting new chapter to a ... Agilents 7890A GC gives you ... your lab to the next ... performance, including advanced separation capabilities, ...
... often call for critical, but time-consuming ... refines siRNA transfection protocols resulting in ... can be used to efficiently transfect ... without increased cytotoxicity. From start ...
... CaspaTag™ Pan-Caspase In Situ Assay Kit is ... caspases in cells undergoing apoptosis. The kit ... use in diagnostic or therapeutic procedures. CHEMICON®s ... a novel approach to detect active caspases. ...
... INTERFERin is a new-generation siRNA transfection ... efficiency at 1 nM siRNA in a ... with excellent cell viability. Using low siRNA ... effects observed when transfecting siRNA at higher ...
Biology Products: